Explore more topics
SEC Form 4 research

IDERA PHARMACEUTICALS, INC. insider transactions

Inspect IDERA PHARMACEUTICALS, INC.'s public SEC insider acquisitions and sales, reporting owners and source receipts.

As of 2026-10-15T08:02:39.132Z

Issuer CIK
0000861838
Reporting owners
68
Officers and directors
31
Jump to a section

What is a Form 4?

Animation: what a Form 4 is, shown with one real example. Sonic Automotive (SAH) reporting owner Paul P. Rusnak bought 13,701 shares at $59.78 on Wednesday, October 7, 2026, transaction code P, an open-market purchase (S is a sale and A is an award from the company). A timeline marks the SEC's two-business-day filing deadline, which ends Friday, October 9. The SEC accepted the Form 4 at 4:33:21 PM ET on October 9, and NexusTrade treats it as public one minute later, at 4:34:21 PM ET. A lamp for NexusTrade's InsiderTrades indicator stays off from the trade date until that moment, then counts one purchase worth 13,701 × $59.78 = $819,045.78.
In this example the shares were bought on Oct 7, 2026, and NexusTrade's InsiderTrades indicator can count the purchase starting at 4:34:21 PM ET on Oct 9, one minute after the SEC accepted the Form 4.

A Form 4 is the SEC filing a company insider, such as an officer, director or 10% owner, uses to report a trade in the company's stock, generally within two business days. The animation follows one real filing as an example: Paul P. Rusnak's purchase of Sonic Automotive (SAH) shares on October 7, 2026.

The same reading applies to every row on this page. The trade date is when the shares changed hands. The available date is when NexusTrade treats the filing as public, and a NexusTrade InsiderTrades indicator counts a purchase (code P) or sale (code S) only from that moment. Code A awards are not counted as purchases.

Recent insider disclosures

This table includes purchases, sales and awards in the public filing record. Awards and open-market purchases are distinct transaction codes. For historical research, use the public availability date to determine when the transaction was knowable.

Read code P as a purchase, S as a sale and A as an award. An award is an acquisition, but it is not an open-market purchase. Open the filing receipt to check the transaction details.

Show the table · 0 rows, 7 columns

Scroll sideways to compare all columns. Select a heading to sort.

No records are available for this view.

Most recent 90-day source activity, up to 50 rows. No rows means no matching recent records, not no historical activity.

Officers and directors in the directory

Show the table · 38 rows, 3 columns

Scroll sideways to compare all columns. Select a heading to sort.

SCHAFER CAROL00012721812
GOWEN MAXINE000128004411
Goldberg Mark Alan000153247530
SOLAND DANIEL B000131848516
MILANO VINCENT000118715930
HARTLEY C KEITH000119299428
Lim Bryant David00017528887
Horobin Joanna00015609595
DOUGHERTY MICHAEL R000103351611
Kirby John J.00015563277
14159, L.P.00015511381,049
667, L.P.00015511392,118
Abdul-Wahab Umari00015620707
AGRAWAL SUDHIR000108560510
Baker Bros. Advisors (GP) LLC00015805752,197
BAKER BROS. ADVISORS LP00012635082,370
Baker Brothers Life Sciences LP00013633642,127
BAKER FELIX00010879404,174
BAKER JULIAN00010879394,416
Bexon Alice00014040611
Casey Mark J000141529726
Fletcher Robert C.00015082312
GERAGHTY JAMES A000123974624
KARR ROBERT W00013285071
MUELLER HANS00013328314
Pillar Invest Corp000153442887
Pillar Pharmaceuticals I LP000153442566
Pillar Pharmaceuticals II, L.P.000156206973
Pillar Pharmaceuticals III, L.P.000157689158
Pillar Pharmaceuticals IV, L.P.000158813045
Pillar Pharmaceuticals V LP00016873126
REARDON WILLIAM S00012126466
Sullivan Timothy M00013752113
Tarka Elizabeth Ann00017830372
WYNGAARDEN JAMES B000102294011
YINGLING JONATHAN MICHAEL00016600111
ZAMECNIK PAUL C00011955649
ZEIN YOUSSEF EL000119336681

Which transactions qualify for the company tracker

The company strategy uses verified officers and directors with qualifying acquisitions at this issuer. Other reporting owners may appear in source records without becoming strategy signals.

Strategy eligibility is held while filing coverage is unresolved.

Historical follower simulations are separate from these source transactions. They do not establish live trading results.